TABLE 1 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE ANXIETY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE DEPRESSION IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE MOOD DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE BIPOLAR DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE EATING DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE PSYCHOTIC DISORDERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 10 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 12 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 13 EUROPE INSTRUMENTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE SOFTWARE AND SERVICES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 20 EUROPE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 26 EUROPE CYP2C19 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE CYP2C9 AND VKORC1 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE CYP2D6 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE HLA-B IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HTR2A/C IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE HLA-A IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE CYP3A4 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE SLC6A4 IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE MTHFR IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE COMT IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE ADULT IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE GERIATRIC IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE CHILD IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 EUROPE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 EUROPE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE DIAGNOSTICS LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 EUROPE OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 49 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 EUROPE DIRECT TENDER IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 51 EUROPE THIRD PARTY DISTRIBUTION IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 52 EUROPE HOSPITAL PHARMACY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE OTHERS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 54 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 55 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 58 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 59 EUROPE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 60 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 61 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 62 EUROPE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 63 EUROPE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 64 EUROPE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 65 EUROPE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 66 EUROPE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 67 EUROPE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 68 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 69 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 EUROPE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 72 EUROPE DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 75 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 77 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 78 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 79 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 81 GERMANY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 82 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 83 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 84 GERMANY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 85 GERMANY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 86 GERMANY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 87 GERMANY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 88 GERMANY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 89 GERMANY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 90 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 91 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 GERMANY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 GERMANY DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 95 GERMANY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 GERMANY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 99 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 100 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 101 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 102 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 103 FRANCE CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 104 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 105 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 106 FRANCE EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 107 FRANCE KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 108 FRANCE LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 109 FRANCE DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 110 FRANCE MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 111 FRANCE CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 112 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 113 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 114 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 115 FRANCE HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 FRANCE DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 117 FRANCE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 118 FRANCE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 119 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 122 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 123 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 124 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 125 U.K. CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 126 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 127 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 128 U.K. EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 129 U.K. KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 130 U.K. LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 131 U.K. DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 132 U.K. MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 133 U.K. CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 134 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 135 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 136 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 137 U.K. HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 138 U.K. DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 U.K. ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 U.K. PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 143 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 144 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 145 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 146 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 147 ITALY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 148 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 149 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 150 ITALY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 151 ITALY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 152 ITALY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 153 ITALY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 154 ITALY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 155 ITALY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 156 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 157 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 158 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 159 ITALY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 160 ITALY DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 161 ITALY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 162 ITALY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 163 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 165 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 166 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 167 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 168 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 169 RUSSIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 170 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 171 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 172 RUSSIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 173 RUSSIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 174 RUSSIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 175 RUSSIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 176 RUSSIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 177 RUSSIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 178 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 179 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 180 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 181 RUSSIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 182 RUSSIA DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 183 RUSSIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 184 RUSSIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 185 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 187 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 188 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 189 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 190 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 191 SPAIN CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 192 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 193 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 194 SPAIN EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 195 SPAIN KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 196 SPAIN LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 197 SPAIN DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 198 SPAIN MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 199 SPAIN CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 200 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 201 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 202 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 203 SPAIN HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 204 SPAIN DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 SPAIN ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 206 SPAIN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 207 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 209 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 210 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 211 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 212 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 213 TURKEY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 214 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 215 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 216 TURKEY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 217 TURKEY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 218 TURKEY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 219 TURKEY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 220 TURKEY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 221 TURKEY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 222 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 223 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 224 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 225 TURKEY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 226 TURKEY DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 227 TURKEY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 228 TURKEY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 229 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 231 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 232 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 233 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 234 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 235 NETHERLANDS CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 236 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 237 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 238 NETHERLANDS EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 239 NETHERLANDS KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 240 NETHERLANDS LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 241 NETHERLANDS DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 242 NETHERLANDS MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 243 NETHERLANDS CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 244 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 245 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 246 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 247 NETHERLANDS HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 248 NETHERLANDS DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 249 NETHERLANDS ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 250 NETHERLANDS PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 251 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 252 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 253 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 254 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 255 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 256 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 257 SWITZERLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 258 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 259 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 260 SWITZERLAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 261 SWITZERLAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 262 SWITZERLAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 263 SWITZERLAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 264 SWITZERLAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 265 SWITZERLAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 266 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 267 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 268 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 269 SWITZERLAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 270 SWITZERLAND DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 271 SWITZERLAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 272 SWITZERLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 273 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 275 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 276 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 277 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 278 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 279 POLAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 280 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 281 POLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 282 POLAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 283 POLAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 284 POLAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 285 POLAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 286 POLAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 287 POLAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 288 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 289 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 290 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 291 POLAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 292 POLAND DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 293 POLAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 294 POLAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 295 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 296 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 297 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 298 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 299 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 300 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 301 HUNGARY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 302 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 303 HUNGARY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 304 HUNGARY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 305 HUNGARY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 306 HUNGARY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 307 HUNGARY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 308 HUNGARY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 309 HUNGARY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 310 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 311 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 312 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 313 HUNGARY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 314 HUNGARY DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 315 HUNGARY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 316 HUNGARY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 317 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 319 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 320 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 321 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 322 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 323 AUSTRIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 324 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 325 AUSTRIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 326 AUSTRIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 327 AUSTRIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 328 AUSTRIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 329 AUSTRIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 330 AUSTRIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 331 AUSTRIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 332 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 333 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 334 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 335 AUSTRIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 336 AUSTRIA DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 337 AUSTRIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 338 AUSTRIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 339 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 340 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 341 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 342 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 343 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 344 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 345 NORWAY CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 346 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 347 NORWAY WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 348 NORWAY EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 349 NORWAY KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 350 NORWAY LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 351 NORWAY DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 352 NORWAY MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 353 NORWAY CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 354 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 355 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 356 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 357 NORWAY HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 358 NORWAY DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 359 NORWAY ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 360 NORWAY PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 361 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 362 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 363 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 364 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 365 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 366 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 367 IRELAND CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 368 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 369 IRELAND WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 370 IRELAND EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 371 IRELAND KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 372 IRELAND LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 373 IRELAND DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 374 IRELAND MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 375 IRELAND CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 376 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 377 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 378 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 379 IRELAND HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 380 IRELAND DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 381 IRELAND ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 382 IRELAND PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 383 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 384 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 385 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 386 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 387 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 388 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 VOLUME (UNITS)
TABLE 389 LITHUANIA CONSUMABLES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT, 2020-2029 ASP (USD)
TABLE 390 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 391 LITHUANIA WHOLE GENOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 392 LITHUANIA EXOME SEQUENCING IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 393 LITHUANIA KARYOTYPE IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 394 LITHUANIA LOW COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 395 LITHUANIA DEEP COVERAGE WGS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 396 LITHUANIA MICROARRAY IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 397 LITHUANIA CHROMOSOMAL ARRAY BASED TESTS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 398 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE, 2020-2029 (USD MILLION)
TABLE 399 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 400 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 401 LITHUANIA HOSPITAL AND CLINICS IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 402 LITHUANIA DIAGNOSTIC LABORATORIES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 403 LITHUANIA ACADEMIC AND RESEARCH INSTITUTES IN PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 404 LITHUANIA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 405 REST OF EUROPE PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2020-2029 (USD MILLION)